TICAGRELOR VS. PRASUGREL IN ACUTE CORONARY SYNDROME: EVIDENCE FROM THE POST-ISAR-REACT 5 ERA.
DOI:
https://doi.org/10.52428/20756208.v20i49.1457Keywords:
Ticagrelor, Prasugrel, Sindrome coronarioAbstract
latter editor
Downloads
References
1. Bergmark BA, Mathenge N, Merlini PA, Lawrence-Wright MB, Giugliano RP. Acute coronary syndromes. Lancet [Internet]. 2022 [Citado el 10 de febrero 2025];399(10332):1347–58. Disponible en: http://dx.doi.org/10.1016/S0140-6736(21)02391-6
2. Rodriguez F, Harrington RA. Management of antithrombotic therapy after acute coronary syndromes. N Engl J Med [Internet]. 2021 [Citado el 10 de febrero 2025];384(5):452–60. Disponible en: http://dx.doi.org/10.1056/NEJMra1607714
3. Valina C, Neumann F-J, Menichelli M, Mayer K, Wöhrle J, Bernlochner I, et al. Ticagrelor or prasugrel in patients with non-ST-segment elevation acute coronary syndromes. J Am Coll Cardiol [Internet]. 2020 [Citado el 10 de febrero 2025];76(21):2436–46. Disponible en: http://dx.doi.org/10.1016/j.jacc.2020.09.584
4. Shah RP, Shafiq A, Hamza M, Maniya MT, Duhan S, Keisham B, et al. Ticagrelor versus prasugrel in patients with acute coronary syndrome: A systematic review and meta-analysis. Am J Cardiol [Internet]. 2023 [Citado el 10 de febrero 2025]; 207:206–14. Disponible en: http://dx.doi.org/10.1016/j.amjcard.2023.08.117
5. Center for Drug Evaluation, Research. Approved Drug Products with Therapeutic Equivalence Evaluations [Internet]. U.S. Food and Drug Administration. FDA; 2025 [citado el 8 de octubre de 2025]. Disponible en: https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
6. Ndrepepa G, et al. Ticagrelor or Prasugrel in Patients with Acute Coronary Syndrome According to Time of Presentation. J Am Heart Assoc. 2022;11(14): e025862. https://pubmed.ncbi.nlm.nih.gov/35789430/
7. Schüpke S, et al. Ticagrelor or Prasugrel for Patients with Acute Coronary Syndrome Treated with Percutaneous Coronary Intervention: A Prespecified Subgroup Analysis of the ISAR-REACT 5 Trial. JAMA Netw Open. 2021;4(6):e2112721. https://pmc.ncbi.nlm.nih.gov/articles/PMC8246339/
8. Angiolillo DJ, et al. Pharmacodynamic Comparison of Ticagrelor and Prasugrel in Patients with Acute Coronary Syndrome: A Systematic Review and Meta-Analysis. Front Cardiovasc Med. 2022; 9:905607. https://www.frontiersin.org/articles/10.3389/fcvm.2022.905607/full
9. De Luca L, et al. Ticagrelor Versus Prasugrel in Acute Coronary Syndrome: Contemporary Evidence and Future Perspectives. Medicina (Kaunas). 2025;61(2):13. https://www.mdpi.com/2305-6320/12/2/13
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Jorge Andrés Hernández Navas, Juan Therán-León, Luis Dulcey-Sarmiento, Jaime Gómez-Ayala
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License 4.0 that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
